Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors

Journal of Medicinal Chemistry

Volumn 49, Issue 1, 2006, Pages 366-372

  Disingrini, Teresa ^a   Muth, Mathias ^b   Dallanoce, Clelia ^a   Barocelli, Elisabetta ^d   Bertoni, Simona ^d   Kellershohn, Kerstin ^c   Mohr, Klaus ^c   De Amici, Marco ^a   Holzgrabe, Ulrike ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,8 NAPHTHALIMIDO 2,2 DIMETHYLPROPANE; METHYLSCOPOLAMINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; NAPHMETHONIUM; OXOTREMORINE; OXOTREMORINE M; PHTHALIMIDOPROPANE; PROPANE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN;

ALLOSTERIC REGULATION; ANIMALS; CHO CELLS; CRICETINAE; DRUG DESIGN; GUINEA PIGS; HUMANS; LIGANDS; MALE; MOLECULAR STRUCTURE; OXOTREMORINE; PHTHALIMIDES; PYRIDONES; RABBITS; RECEPTORS, MUSCARINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 30444436744     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050769s     Document Type: Article

References (47)

1. Felder, C. C.; Bymaster, F. P.; Ward, J.; DeLapp, N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J. Med. Chem. 2000, 43, 4333-4353, and references therein.
2. Eglen, R. M.; Choppin, A.; Watson, N. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol. Sci. 2001, 22, 409-414, and references therein.
3. Hulme, E. C.; Birdsall, N. J. M.; Buckley, N. J. Muscarinic receptor subtypes. Annu. Rev. Pharmacol. Toxicol. 1990, 30, 633-673.
4. Caulfield, M. P.; Birdsall, N. J. M. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 1998, 50, 279-290.
5. Wess, J. Novel insights into muscarinic acetylcholine receptor function using gene targeting technology. Trends Pharmacol. Sci. 2003, 24, 414-420.
6. Wess, J.; Duttaroy, A.; Gomeza, J.; Zhang, W.; Yamada, M.; Felder, C. C.; Bernardini, N.; Reeh, P. W. Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice: a review. Life Sci. 2003, 72, 2047-2054.
7. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Rev. Drug Discovery 2002, 1, 198-210, and references therein.
8. 2 muscarinic acetylcholine receptors. Mol. Pharmacol. 1994, 45, 983-990.
9. Tuček, S.; Proška, J. Allosteric modulation of muscarinic acetylcholine receptors. Trends Pharmacol. Sci. 1995, 16, 205-212.
10. Ellis, J. Allosteric binding site on muscarinic receptors. Drug. Dev. Res. 1997, 40, 193-204.
11. Holzgrabe, U.; Mohr, K. Allosteric modulators of ligand binding to muscarinic acetylcholine receptors. Drug Discovery Today 1998, 3, 214-222.
12. Birdsall, N. J. M.; Lazareno, S. Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev. Med. Chem. 2005, 5, 523-543.
13. 2 muscarinic allosteric modulators. Recept. Channels 2003, 9, 229-240.
14. 5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol. Pharmacol. 2003, 64, 21-31.
15. 2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type W84. Mol. Pharmacol. 2005, 68, 769-778.
16. 3H-N-methylscopolamine binding in guinea-pig myocardium by an antidote against organophosphorus intoxication. J. Pharmacol. Toxicol. 1988, 63, 163-168.
17. 2 receptors. Mol. Pharmacol. 1998, 54, 139-145.
18. Muth, M.; Bender, W.; Scharfenstein, O.; Holzgrabe, U.; Balatkova, E.; Tränkle, C.; Mohr, K. Systematic development of high affinity bis(ammonio)alkane-type allosteric enhancers of muscarinic ligand binding. J. Med. Chem. 2003, 46, 1031-1040.
19. Muth, M.; Sennwitz, M.; Mohr, K.; Holzgrabe, U. Muscarinic allosteric enhancers of ligand binding: pivotal pharmacophoric elements in hexamethonio-type agents. J. Med. Chem. 2005, 48, 2212-2217.
20. 2 receptor binding of the selective antagonist AF-DX 384: possible involvement of the common allosteric site. Mol. Pharmacol. 1998, 53, 304-312.
21. Lüllmann, H.; Ohnesorge, F. K.; Schauwecker, G. C.; Wassermann, O. Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. Eur. J. Pharmacol. 1969, 6, 241-247.
22. Dallanoce, C.; Conti, P.; De Amici, M.; De Micheli, C.; Barocelli, E.; Chiavarini, M.; Ballabeni, V.; Bertoni, S.; Impicciatore, M. Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M. Bioorg. Med. Chem. 1999, 7, 1539-1547.
23. Barocelli, E.; Ballabeni, V.; Bertoni, S.; Dallanoce, C.; De Amici, M.; De Micheli, C.; Impicciatore, M. New analogues of oxotremorine and oxotremorine-M: estimation of their in vitro affinity and efficacy at muscarinic receptor subtypes. Life Sci. 2000, 67, 717-723.
24. Barocelli, E.; Ballabeni, V.; Bertoni, S.; De Amici, M.; Impicciatore, M. Evidence for specific analgesic activity of muscarinic agonists selected among a new series of acetylenic derivatives. Life Sci. 2001, 68, 1775-1785.
25. De Amici, M.; Conti, P.; Fasoli, E.; Barocelli, E.; Ballabeni, V.; Bertoni, S.; Impicciatore, M.; Roth, B. L.; Ernsberger, P.; De Micheli, C. Synthesis and in vitro pharmacology of novel heterocyclic muscarinic ligands. Il Farmaco 2003, 58, 739-748.
26. Masuyama, Y.; Watabe, A.; Ito, A.; Kurusu, Y. Carbonyl propargylation by 1-substituted prop-2-ynyl mesylates and carbonyl allenylation by 3-substituted prop-2-ynyl mesylates with tin (II) iodide and tetrabutylammonium iodide. Chem. Commun. 2000, 2009-2010.
27. Nilsson, B. M.; Vargas, H. M.; Hacksell, U. Urea and 2-imidazolone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4- pyrrolidino-2-butynyl)acetamide. J. Med. Chem. 1992, 35, 3270-3279.
28. Bebbington, A.; Shakeshaft, D. An improved synthesis of oxotremorine. J. Med. Chem. 1965, 8, 274-275.
29. Garvey, D. S.; Wasicak, J. T.; Chung, J. Y.-L.; Shue, Y.-K.; Carrera, G. M.; May, P. D.; McKinney, M. M.; Anderson, D.; Cadman, E.; Vella-Rountree, L.; Nadzan, A. M.; Williams, M. Synthesis and in vitro characterization of novel amino terminally modified oxotremorine derivatives for brain muscarinic receptors. J. Med. Chem. 1992, 35, 1550-1557, and references therein.
30. Iwai, I.; Nakamura, N. Studies on acetylenic compounds. XLIV. Synthesis of 3-aminoisoxazoles and 3-hydroxyisoxazoles (3-isoxazolones). Chem. Pharm. Bull. 1966, 14, 1277-1286.
31. 2-receptors. Life Sci. 2000, 66, 1675-1682.
32. Ehlert, F. J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 1988, 33, 187-194.
33. Stockton, J. M.; Birdsall, N. J. M.; Burgen, A. S. V.; Hulme, E. C. Modification of the binding properties of the muscarinic receptors by gallamine. Mol. Pharmacol. 1983, 23, 551-557.
34. 2 muscarinic acetylcholine receptors: structure/activity relationships in stepwise shortened bispyridinium- and bis(ammonio)alkane-type allosteric modulators. Neurochem. Res. 2003, 28, 667-673.
35. Schmalenbach, C.; Muth, M.; Tränkle, C.; Holzgrabe, U.; Mohr, K. Effect of the muscarinic alloster naphmethonium on acetylcholine induced G protein activation. Book of Abstracts, Annual Meeting of the German Pharmaceutical Society, Würzburg, P P15, page 104, 2003.
36. 2 receptors mediating opposite effects on neuromuscular transmission in rabbit vas deferens. Eur. J. Pharmacol. 1988, 151, 205-221.
37. Harvey, A. L.; Kornisiuk, E.; Bradley, K. N.; Cervenansky, C.; Durán, R.; Sánchez, G.; Jerusalinsky, D. Effects of muscarinic toxins MT1 and MT2 from green mamba on different muscarinic cholinoceptors. Neurochem. Res. 2002, 27, 1543-1554.
38. Ringdahl, B. Selectivity of partial agonists related to oxotremorine based on differences in muscarinic receptor reserve between the guinea pig ileum and urinary bladder. Mol. Pharmacol. 1987, 31, 351-356.
39. 2 acetylcholine receptors: Search for the minimum essential distances between the pharmacophoric elements. J. Med. Chem. 1999, 42, 849-858.
40. 2 receptors: SAR and QSAR studies in a series of bisquaternary salts of caracurine V and related ring systems. J. Med. Chem. 2004, 47, 3561-3571.
41. Kostenis, E.; Mohr, K. Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol Sci. 1996, 17, 280-283.
42. Lazareno, S.; Birdsall, N. J. M. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G-protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 1995, 48, 362-378.
43. Van Rossum, J. M. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch. Int. Pharmacodyn. 1963, 143, 299-330.
44. McKay, D. A. General analysis of the receptor-drug interaction. Br. J. Pharmacol. 1966, 26, 9-16.
45. Furchgott, R. F. The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. Handbook of Experimental Pharmacology; Blanschko, H., Muscholl, E., Eds.; Springer: New York, 1972; Issue 33, pp 283-335.
46. Zahn, K.; Eckstein, N.; Tränkle, C.; Sadee, W.; Mohr, K. Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. J. Pharmacol. Exp. Ther. 2002, 2, 720-728.
47. bladder. Mol. Pharmacol. 1987, 31, 351-356.